Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Holdings Boosted by State Street Corp

State Street Corp grew its holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 29.4% in the third quarter, Holdings Channel.com reports. The firm owned 253,946 shares of the company’s stock after purchasing an additional 57,674 shares during the period. State Street Corp’s holdings in Lexeo Therapeutics were worth $2,296,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Janus Henderson Group PLC raised its position in Lexeo Therapeutics by 18.9% during the third quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock valued at $33,997,000 after buying an additional 599,203 shares during the period. Vestal Point Capital LP grew its stake in Lexeo Therapeutics by 1.2% during the 3rd quarter. Vestal Point Capital LP now owns 850,000 shares of the company’s stock valued at $7,684,000 after acquiring an additional 10,000 shares in the last quarter. Verition Fund Management LLC increased its holdings in shares of Lexeo Therapeutics by 84.5% in the 3rd quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock valued at $7,027,000 after purchasing an additional 355,928 shares during the period. Point72 Asset Management L.P. purchased a new stake in shares of Lexeo Therapeutics in the third quarter worth approximately $3,348,000. Finally, Ikarian Capital LLC acquired a new stake in shares of Lexeo Therapeutics during the third quarter worth approximately $2,325,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on LXEO shares. HC Wainwright upped their price target on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 14th. Chardan Capital upped their target price on Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, Leerink Partners cut their price target on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Wednesday, November 13th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Lexeo Therapeutics has an average rating of “Buy” and an average target price of $23.80.

Insider Transactions at Lexeo Therapeutics

In other news, CEO Richard Nolan Townsend sold 5,000 shares of the business’s stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $8.10, for a total value of $40,500.00. Following the completion of the sale, the chief executive officer now directly owns 120,695 shares in the company, valued at approximately $977,629.50. The trade was a 3.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders sold 10,000 shares of company stock worth $80,550. 4.50% of the stock is owned by corporate insiders.

Lexeo Therapeutics Trading Up 0.6 %

Shares of NASDAQ:LXEO opened at $6.58 on Wednesday. Lexeo Therapeutics, Inc. has a 1 year low of $5.77 and a 1 year high of $22.33. The firm has a fifty day moving average price of $7.48 and a 200 day moving average price of $10.33. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $217.57 million and a PE ratio of -2.08.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.